Teva Targets BioXcel’s IGALMI and BXCL501 Assets in Strategic Acquisition Deal

Key Points

• BioXcel filed Chapter 11 cases in Delaware to conduct a court-supervised sale of substantially all company assets.
• Teva Pharmaceuticals International GmbH signed an asset-purchase agreement and will serve as the stalking-horse bidder.
• The proposed sale includes IGALMI and the pending BXCL501 supplemental FDA application.
• BioXcel has a commitment for $19 million in debtor-in-possession financing, subject to bankruptcy-court approval.
• IGALMI is expected to remain available to patients during the Chapter 11 process.
• The FDA’s target action date for the BXCL501 at-home-use application is November 14, 2026.

 BioXcel Therapeutics (NASDAQ: BTAI) has signed an asset-sale agreement with Teva Pharmaceuticals, which will act as the stalking-horse bidder for substantially all of BioXcel’s assets. The court-supervised sale centers on IGALMI and BioXcel’s BXCL501 regulatory program, while the company seeks to continue operations during the restructuring process.

Teva’s Stalking-Horse Bid Sets the Starting Point for a BioXcel Asset Auction

Teva’s agreement provides an initial bid for BioXcel’s assets and establishes the starting point for a Section 363 bankruptcy auction. BioXcel can seek higher or otherwise better offers from other potential buyers before a sale is finalized.

The agreement does not guarantee that Teva will become the final buyer. The transaction remains subject to bankruptcy-court approval, auction results, and satisfaction of closing conditions.

IGALMI and BXCL501 Are the Core Assets in BioXcel’s Sale Process

The sale includes IGALMI, BioXcel’s FDA-approved dexmedetomidine sublingual film for acute agitation associated with schizophrenia or bipolar I or II disorder in adults under healthcare-provider supervision.

It also includes the pending BXCL501 supplemental New Drug Application seeking at-home use for agitation associated with bipolar I or II disorder in adults. The FDA is expected to act on that application by November 14, 2026.

$19 Million DIP Financing Is Intended to Keep Operations Running

BioXcel secured a $19 million commitment for debtor-in-possession financing from its existing secured lenders, pending court approval. The funding is intended to support normal operations, preserve product supply, meet post-petition obligations, and maintain employee, customer, and patient-support programs while the sale proceeds.

What the Chapter 11 Sale Means for BTAI Shareholders

The Chapter 11 filing is designed to maximize the value of BioXcel’s assets, but it does not mean common shareholders will receive value. Secured lenders and other creditors generally rank ahead of equity holders in bankruptcy.

For BTAI investors, the key events to watch are court approval of the sale and financing, Teva’s proposed bid terms, any competing offers, the FDA’s BXCL501 decision, the final sale price, and the level of debt and claims that must be paid before any potential recovery could reach shareholders. BioXcel has also warned that its Nasdaq listing may be affected during the restructuring process.